Avadel Pharmaceuticals PLC (STU:AWK)
€ 9.85 0.4 (4.23%) Market Cap: 949.15 Mil Enterprise Value: 888.38 Mil PE Ratio: 0 PB Ratio: 13.32 GF Score: 40/100

Avadel Pharmaceuticals PLC Business Update Transcript

May 01, 2023 / 08:00PM GMT
Release Date Price: €8.7
Operator

Greetings, and welcome to the Avadel Pharmaceuticals Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce Austin Murtagh. Thank you, and you may begin.

Austin Murtagh

Good afternoon, and thank you for joining us on our conference call to discuss the final FDA approval of LUMRYZ. You can access the press release announcing the approval on our website, www.avadel.com.

As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.

These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot